← Back to Screener
Ocular Therapeutix, Inc. (OCUL)
Price$9.52
Favorite Metrics
Price vs S&P 500 (26W)-25.39%
Price vs S&P 500 (4W)10.56%
Market Capitalization$2.09B
All Metrics
Book Value / Share (Quarterly)$3.03
P/TBV (Annual)5.03x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)0.30%
Cash Flow / Share (Quarterly)$-1.00
Price vs S&P 500 (YTD)-23.25%
Gross Margin (TTM)87.35%
Net Profit Margin (TTM)-511.90%
EPS (TTM)$-1.44
10-Day Avg Trading Volume3.51M
EPS Excl Extra (TTM)$-1.44
Revenue Growth (5Y)24.45%
EPS (Annual)$-1.42
ROI (Annual)-36.65%
Gross Margin (Annual)87.35%
Net Profit Margin (5Y Avg)-221.35%
Cash / Share (Quarterly)$3.41
Revenue Growth QoQ (YoY)-22.43%
ROA (Last FY)-32.91%
Revenue Growth TTM (YoY)-18.39%
EBITD / Share (TTM)$-1.42
ROE (5Y Avg)-79.74%
Operating Margin (TTM)-519.75%
Cash Flow / Share (Annual)$-1.00
P/B Ratio3.20x
P/B Ratio (Quarterly)3.95x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)27.45x
Net Interest Coverage (TTM)-5.44x
ROA (TTM)-51.24%
EPS Incl Extra (Annual)$-1.42
Current Ratio (Annual)15.39x
Quick Ratio (Quarterly)15.11x
3-Month Avg Trading Volume5.50M
52-Week Price Return36.96%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.10
P/S Ratio (Annual)40.27x
Asset Turnover (Annual)0.06x
52-Week High$16.44
Operating Margin (5Y Avg)-256.39%
EPS Excl Extra (Annual)$-1.42
CapEx CAGR (5Y)70.24%
Tangible BV CAGR (5Y)6.23%
26-Week Price Return-16.64%
Quick Ratio (Annual)15.11x
13-Week Price Return-11.29%
Total Debt / Equity (Annual)0.11x
Current Ratio (Quarterly)15.39x
Enterprise Value$1,426.294
Revenue / Share Growth (5Y)-0.63%
Asset Turnover (TTM)0.10x
Book Value / Share Growth (5Y)24.79%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)1.99x
Pretax Margin (Annual)-511.90%
Cash / Share (Annual)$3.41
3-Month Return Std Dev96.41%
Gross Margin (5Y Avg)90.11%
Net Income / Employee (TTM)$-1
ROE (Last FY)-40.64%
Net Interest Coverage (Annual)-189.25x
EPS Basic Excl Extra (Annual)$-1.42
Receivables Turnover (TTM)1.65x
Total Debt / Equity (Quarterly)0.11x
EPS Incl Extra (TTM)$-1.44
Receivables Turnover (Annual)1.65x
ROI (TTM)-60.25%
P/S Ratio (TTM)40.27x
Pretax Margin (5Y Avg)-221.35%
Revenue / Share (Annual)$0.28
Tangible BV / Share (Annual)$0.46
Price vs S&P 500 (52W)1.86%
Year-to-Date Return-19.11%
5-Day Price Return10.84%
EPS Normalized (Annual)$-1.42
ROA (5Y Avg)-31.60%
Net Profit Margin (Annual)-511.90%
Month-to-Date Return15.94%
Cash Flow / Share (TTM)$-0.83
EBITD / Share (Annual)$-1.42
Operating Margin (Annual)-519.75%
LT Debt / Equity (Annual)0.11x
ROI (5Y Avg)-43.97%
LT Debt / Equity (Quarterly)0.11x
EPS Basic Excl Extra (TTM)$-1.44
P/TBV (Quarterly)22.65x
P/B Ratio (Annual)3.95x
Inventory Turnover (TTM)1.99x
Pretax Margin (TTM)-511.90%
Book Value / Share (Annual)$3.03
Price vs S&P 500 (13W)-14.16%
Beta0.96x
Revenue / Share (TTM)$0.23
ROE (TTM)-71.66%
52-Week Low$6.23
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.32
4.32
4.32
4.28
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
OCULOcular Therapeutix, Inc. | 40.27x | -18.39% | 87.35% | — | $9.52 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Ocular Therapeutix is a biotechnology company developing innovative eye disease treatments using its proprietary hydrogel platform technology, which enables improved therapeutic delivery compared to traditional eye drops. The company's pipeline includes multiple product candidates across various ophthalmic indications, including the FDA-approved Dextenza. Its platform technology addresses key limitations of conventional eye-drop therapies, positioning the company to capture market share in large ophthalmic disease markets.